

Xuhong Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3571159/publications.pdf>

Version: 2024-02-01

58
papers

12,460
citations

101543

36
h-index

155660

55
g-index

58
all docs

58
docs citations

58
times ranked

21683
citing authors

#	ARTICLE	IF	CITATIONS
1	Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2022, 142, 641-652.	0.7	9
2	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature, 2022, 601, 434-439.	27.8	110
3	Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i> . Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	142
4	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncology, 2021, 7, 525-533.	7.1	65
5	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. Clinical Cancer Research, 2021, 27, 3079-3093.	7.0	8
6	AGO2 promotes tumor progression in KRAS-driven mouse models of nonâ€‘small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
7	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	136
8	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 978-993.	13.2	52
9	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine, 2021, 27, 152-164.	30.7	451
10	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia, 2020, 22, 111-119.	5.3	101
11	An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. Nature Communications, 2020, 11, 2817.	12.8	29
12	Next-generation RNA Sequencingâ€‘based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. European Urology, 2020, 78, 63-74.	1.9	57
13	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. Neuro-Oncology, 2020, 22, iii298-iii299.	1.2	0
14	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature, 2019, 571, 413-418.	27.8	192
15	Functional and Mechanistic Interrogation of BET Bromodomain Degradors for the Treatment of Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 4038-4048.	7.0	26
16	Characterizing the Therapeutic Potential of a Potent BET Degradator in Merkel Cell Carcinoma. Neoplasia, 2019, 21, 322-330.	5.3	10
17	The Landscape of Circular RNA in Cancer. Cell, 2019, 176, 869-881.e13.	28.9	1,095
18	Targeting the MYCNâ€‘PARPâ€‘DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clinical Cancer Research, 2018, 24, 696-707.	7.0	80

#	ARTICLE	IF	CITATIONS
19	Clinical validation of the Tempus xO assay. <i>Oncotarget</i> , 2018, 9, 25826-25832.	1.8	43
20	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-34.	3.0	10
21	MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. <i>Neoplasia</i> , 2018, 20, 1144-1149.	5.3	20
22	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	21.4	196
23	Genetic diversity of NDUFV1-dependent mitochondrial complex I deficiency. <i>European Journal of Human Genetics</i> , 2018, 26, 1582-1587.	2.8	15
24	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 483-486.	1.9	86
25	DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG. <i>Neuro-Oncology</i> , 2018, 20, i56-i56.	1.2	0
26	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018, 173, 1770-1782.e14.	28.9	400
27	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA <i>In Situ</i> Hybridization Assay. <i>Clinical Cancer Research</i> , 2017, 23, 5622-5630.	7.0	31
28	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , 2017, 31, 532-548.e7.	16.8	85
29	Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. <i>Npj Precision Oncology</i> , 2017, 1, 32.	5.4	17
30	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	27.8	685
31	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	5.0	12
32	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , 2017, 171, 1559-1572.e20.	28.9	200
33	Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw200.	6.3	150
34	Next generation sequencing of extraskeletal myxoid chondrosarcoma. <i>Oncotarget</i> , 2017, 8, 21770-21777.	1.8	20
35	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. <i>Cell Reports</i> , 2016, 17, 2620-2631.	6.4	68
36	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 489-499.	5.3	55

#	ARTICLE	IF	CITATIONS
37	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nature Communications, 2016, 7, 12791.	12.8	196
38	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia, 2016, 18, 1-9.	5.3	25
39	KRAS Engages AGO2 to Enhance Cellular Transformation. Cell Reports, 2016, 14, 1448-1461.	6.4	41
40	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. European Urology Focus, 2016, 1, 265-268.	3.1	45
41	<i>De novo</i> dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. Human Molecular Genetics, 2016, 25, 597-608.	2.9	56
42	Identification of clinically actionable pharmacogenetic variants during tumor genetic profiling in pediatric cancer patients.. Journal of Clinical Oncology, 2016, 34, 1583-1583.	1.6	2
43	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget, 2016, 7, 52888-52899.	1.8	18
44	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660
45	The landscape of antisense gene expression in human cancers. Genome Research, 2015, 25, 1068-1079.	5.5	150
46	The landscape of long noncoding RNAs in the human transcriptome. Nature Genetics, 2015, 47, 199-208.	21.4	2,410
47	Targeting the MLL complex in castration-resistant prostate cancer. Nature Medicine, 2015, 21, 344-352.	30.7	165
48	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Research, 2015, 25, 1372-1381.	5.5	139
49	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA - Journal of the American Medical Association, 2015, 314, 913.	7.4	333
50	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. Cancer Research, 2015, 75, 3720-3727.	0.9	276
51	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. Blood, 2015, 126, 647-647.	1.4	0
52	Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Science Translational Medicine, 2014, 6, 252ra122.	12.4	86
53	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nature Communications, 2014, 5, 5893.	12.8	121
54	The central role of EED in the orchestration of polycomb group complexes. Nature Communications, 2014, 5, 3127.	12.8	130

#	ARTICLE	IF	CITATIONS
55	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature, 2014, 510, 278-282.	27.8	811
56	The lncRNA <i>PCAT29</i> Inhibits Oncogenic Phenotypes in Prostate Cancer. Molecular Cancer Research, 2014, 12, 1081-1087.	3.4	119
57	Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. Journal of Clinical Oncology, 2014, 32, e16038-e16038.	1.6	1
58	Tomlins et al. reply. Nature, 2009, 457, E2-E3.	27.8	6